Vivo Bio Tech has successfully secured approval from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), obtained funding from a financial institution, and completed the development of a state-of-the-art large animal facility. This advanced 15,000 sq. ft. facility, co-funded through internal accruals and institutional debt, is designed to house, breed, and conduct studies on canines, pigs, mini-pigs, sheep, and goats. Operations have already commenced at the facility, which offers a wide range of services, including Pharmacokinetic (PK), Pharmacodynamic (PD), Surgical Studies, and Toxicology Studies. These services are being provided to an expanding list of major pharmaceutical and bio-pharmaceutical companies.
This new capability significantly strengthens Vivo Bio Tech’s existing ecosystem, which encompasses In-vitro and In-vivo Small Animal Studies, Eco-Toxicology, Analytical, and Bio-analytical services. The addition of this large animal facility enables the company to deliver comprehensive Investigational New Drug (IND) packages to pharmaceutical and biotech companies worldwide. Vivo Bio Tech now proudly joins an elite group of Contract Research Organizations (CROs) capable of supporting diverse research and development needs across both large and small animal models. Furthermore, the company is committed to expanding its capabilities to position itself as a joint discovery partner for large pharmaceutical organizations.
Vivo Bio Tech (VBTL) is a contract research company engaged in biotechnology and pharma drug discovery activities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1731.20 |
| Dr. Reddys Lab | 1162.35 |
| Cipla | 1483.00 |
| Lupin | 2019.20 |
| Zydus Lifesciences | 891.05 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
100% Secure Process
Account Discovery
- OTP from CAMS
Account Linking for Stocks & MF
- One OTP per link Eg. NSDL, CDSL, CAMS, KFin etc.
One Click Upload for your Current Portfolio and Future Transactions!
Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
